{
  "nctId": "NCT06987032",
  "briefTitle": "Hemodynamics in Chronic Kidney Disease",
  "officialTitle": "Improving the Hemodynamic Profile Of Chronic Renal Patients by Use of Bioimpedance",
  "protocolDocument": {
    "nctId": "NCT06987032",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2019-12-03",
    "uploadDate": "2025-04-15T09:47",
    "size": 1497003,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT06987032/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 71,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2021-01-09",
    "completionDate": "2022-03-09",
    "primaryCompletionDate": "2022-03-09",
    "firstSubmitDate": "2025-03-21",
    "firstPostDate": "2025-05-23"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Prevalent non-dialysis patients with estimated glomerular filtration rate \\< 60 ml/min (for chronic kidney disease subjects)\n* Age \\> 18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Acute kidney injury\n* estimated glomerular filtration rate \\< 20ml/min directly post-nephrectomy\n* Clinical conditions affecting bioimpedance measurements: limb amputation, impaired skin integrity, brain stimulator, pacemaker with low threshold or unipolar pacemaker.\n* Clinical conditions affecting body composition: liver cirrhosis, active infectious disease or any acute cardiovascular event (defined as cerebrovascular event, myocard infarction, heart failure) during the 3 months before screening for inclusion\n* Pregnancy",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "whole body fluid status",
        "description": "The primary objective is to associate the bioimpedance-determined fluid status \\[fluid overload versus non-fluid overload\\] with kidney function decline in patients with chronic kidney disease stage 3 (59-30ml/min), 4 (29-15ml/min) and 5 (\\< 15 ml/min).",
        "timeFrame": "Baseline, every 3 months during 1 year"
      }
    ],
    "secondary": [
      {
        "measure": "identify the clinical factors associated with fluid overload during a longitudinal follow up",
        "description": "Secondary outcomes of interest are the central volume status (measured as ejection fraction in % by echocardiography and thoracic bioimpedance in Ohms in combination with photoplethysmography), the cardiac systolic and diastolic function (measured by echocardiography), cardiovascular events, hospitalizations, inflammatory- and nutrition status (by whole body bioimpedance measurements), and quality of life (by Short Form 36 questionnaire).",
        "timeFrame": "Baseline, every 3 months during 1 year"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 34,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:08.238Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}